COM:TELIXPHARMA
Telix Pharmaceuticals Limited
- Stock
Last Close
27.12
14/02 05:10
Market Cap
6.49B
Beta: -
Volume Today
784.44K
Avg: -
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '15 | Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|---|---|---|---|
average inventory | 469.87K - | 592.26K 26.05% | 587.50K 0.80% | 2.04M 247.83% | 5.97M 191.93% | 12.89M 116.13% | ||||
average payables | 1.76M - | 5.11M 189.76% | 6.39M 25.06% | 8.85M 38.52% | 14.35M 62.16% | 24.82M 73.03% | ||||
average receivables | 4.39M - | 10.25M 133.71% | 12.23M 19.33% | 15.91M 30.03% | 29.39M 84.71% | 52.07M 77.17% | ||||
book value per share | 0.39 - | 0.26 32.04% | 0.30 14.70% | 0.31 2.30% | 0.01 97.51% | 0.26 3,268.06% | 0.47 81.14% | |||
capex per share | -0.00 - | -0.00 - | -0.00 37.57% | -0.00 279.10% | -0.04 840.41% | -0.03 24.21% | ||||
capex to depreciation | -1.49 - | -2.58 - | ||||||||
capex to operating cash flow | 0.02 - | -0.16 919.08% | 0.02 113.74% | 0.14 522.24% | -0.45 421.81% | |||||
capex to revenue | -0.13 - | -0.07 48.76% | -0.27 297.33% | -0.09 67.49% | -0.02 75.54% | |||||
cash per share | 0.38 - | 0.13 66.53% | 0.19 49.84% | 0.30 58.58% | 0.08 74.23% | 0.37 379.56% | 0.39 3.10% | |||
days of inventory on hand | 77.79 - | 114.15 46.74% | 494.78 333.44% | 50.26 89.84% | 33.58 33.20% | |||||
days payables outstanding | 999.55 - | 1.05K 4.79% | 1.70K 62.54% | 99.65 94.15% | 63.70 36.08% | |||||
days sales outstanding | 15.78K - | 1.26K 91.99% | 967.02 23.51% | 1.45K 49.65% | 92.09 93.64% | 47.61 48.30% | ||||
debt to assets | 0.01 - | 0.02 233.44% | 0.02 7.87% | 0.01 32.67% | 0.02 65.34% | 0.04 76.93% | 0.04 7.07% | |||
debt to equity | 0.01 - | 0.03 366.42% | 0.03 6.97% | 0.03 8.14% | 1.18 4,112.35% | 0.13 88.90% | 0.12 10.27% | |||
dividend yield | ||||||||||
earnings yield | -0.08 - | -0.11 37.33% | -0.08 26.84% | -0.05 40.07% | -0.04 20.25% | -0.05 25.19% | 0.00 103.51% | |||
enterprise value | 34.78M - | 107.34M 208.60% | 319.36M 197.53% | 896.75M 180.79% | 2.17B 141.72% | 2.15B 0.70% | 3.11B 44.56% | |||
enterprise value over ebitda | -5.47 - | -6.85 25.27% | -13.05 90.56% | -21.41 64.13% | -30.93 44.46% | -24.79 19.86% | 130.90 628.03% | |||
ev to operating cash flow | -5.17 - | -13.69 164.56% | 457.52 3,442.74% | -36.54 107.99% | -21.81 40.31% | 130.28 697.37% | ||||
ev to sales | 550.05 - | 91.64 83.34% | 191.61 109.10% | 442.55 130.96% | 13.80 96.88% | 6.26 54.60% | ||||
free cash flow per share | -0.00 - | -0.10 232,766.63% | -0.10 0.67% | 0.01 106.24% | -0.21 3,476.47% | -0.36 68.55% | 0.04 111.32% | |||
free cash flow yield | -0.00 - | -0.16 232,766.63% | -0.07 58.35% | 0.00 102.56% | -0.03 1,746.85% | -0.05 79.68% | 0.00 108.16% | |||
graham net net | 0.37 - | 0.04 88.48% | 0.09 115.02% | 0.03 62.87% | -0.25 821.82% | -0.08 66.90% | -0.22 165.50% | |||
graham number | 0.66 - | 0.63 3.39% | 0.90 41.46% | 1.10 22.28% | 0.22 79.82% | 1.39 528.92% | 0.41 70.29% | |||
income quality | 1.50 - | 0.95 - | ||||||||
intangibles to total assets | 0 - | 0 | 0.03 Infinity% | 0.51 1,642.49% | 0.41 20.51% | 0.38 8.26% | 0.51 35.32% | 0.23 54.48% | 0.28 19.19% | |
interest coverage | -677.34 - | -540.52 20.20% | -11.92 97.79% | -39.80 233.73% | -14.42 63.76% | -14.37 0.34% | 1.30 109.02% | |||
interest debt per share | 0.00 - | 0.01 213.78% | 0.02 123.53% | 0.01 32.39% | 0.03 109.10% | 0.05 97.48% | 0.10 76.51% | |||
inventory turnover | 4.69 - | 3.20 31.85% | 0.74 76.93% | 7.26 884.35% | 10.87 49.69% | |||||
invested capital | 0.01 - | 0.03 366.42% | 0.03 6.97% | 0.03 8.14% | 1.18 4,112.35% | 0.13 88.90% | 0.12 10.27% | |||
market cap | 83.20M - | 131.38M 57.92% | 361.83M 175.40% | 972.48M 168.77% | 2.19B 124.90% | 2.26B 3.26% | 3.22B 42.46% | |||
net current asset value | 47.74M - | 12.05M 74.76% | 26.15M 116.98% | 14.82M 43.32% | -60.11M 505.53% | -2.11M 96.48% | -24.54M 1,061.52% | |||
net debt to ebitda | 7.61 - | 1.53 79.84% | 1.73 13.13% | 1.81 4.24% | 0.28 84.61% | 1.22 338.26% | -4.45 464.97% | |||
net income per share | -0.05 - | -0.07 37.33% | -0.12 74.47% | -0.17 46.15% | -0.29 63.51% | -0.34 17.44% | 0.02 104.87% | |||
operating cash flow per share | -0.10 - | -0.10 2.62% | 0.01 107.62% | -0.21 2,859.49% | -0.32 51.13% | 0.07 123.55% | ||||
payables turnover | 0.37 - | 0.35 4.57% | 0.21 38.47% | 3.66 1,608.32% | 5.73 56.44% | |||||
receivables turnover | 0.02 - | 0.29 1,148.07% | 0.38 30.74% | 0.25 33.18% | 3.96 1,471.53% | 7.67 93.44% | ||||
research and ddevelopement to revenue | 95.79 - | 6.07 93.66% | 4.93 18.77% | 6.97 41.29% | 0.37 94.68% | 0.26 30.06% | ||||
return on tangible assets | -0.13 - | -0.37 188.63% | -0.46 23.76% | -0.46 0.94% | -1.49 227.10% | -0.53 64.40% | 0.02 103.41% | |||
revenue per share | 0.00 - | 0.01 1,446.32% | 0.02 21.85% | 0.02 4.59% | 0.50 2,793.11% | 1.56 209.89% | ||||
roe | -0.13 - | -0.26 102.06% | -0.40 52.11% | -0.57 42.86% | -37.31 6,467.39% | -1.30 96.51% | 0.03 102.69% | |||
roic | -0.13 - | -0.25 96.67% | -0.35 38.29% | -0.53 50.85% | -10.43 1,879.17% | -1.00 90.44% | 0.16 116.51% | |||
sales general and administrative to revenue | 43.56 - | 3.24 92.57% | 3.85 18.92% | 7.13 85.30% | 0.50 93.05% | 0.16 67.92% | ||||
shareholders equity per share | 0.39 - | 0.26 32.04% | 0.30 14.70% | 0.31 2.30% | 0.01 97.51% | 0.26 3,268.06% | 0.47 81.14% | |||
stock based compensation to revenue | ||||||||||
tangible asset value | 47.78M - | 13.45M 71.85% | 28.13M 109.11% | 19.83M 29.52% | -53.57M 370.19% | 21.02M 139.24% | 39.25M 86.69% | |||
tangible book value per share | 0.37 - | 0.07 82.17% | 0.12 81.06% | 0.08 36.05% | -0.19 346.32% | 0.07 135.65% | 0.12 81.70% | |||
working capital | 48.08M - | 27.61M 42.56% | 48.05M 74.02% | 73.67M 53.31% | 9.56M 87.02% | 87.68M 817.03% | 67.44M 23.08% |
All numbers in AUD (except ratios and percentages)